Clinical trials: Blood Plasma Therapy
Multiple Myeloma
WT1 Vaccine Treatment of Patients With Multiple Myeloma After Autologous Stem Cell Transplantation
The purpose of this trial is to assess the immune response after vaccination with a peptide vaccine called galinpepimut-S (or GPS) in a type of blood cancer called multiple myeloma.
- Trial name
- NCT01827137
- Testing
- Galinpepimut-S, GM-CSF, Montanide
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Sellas Life Sciences Group
Chronic Myeloproliferative Disorders, Leukemia
Pyroxamide in Treating Patients With Advanced Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of pyroxamide in treating patients who have advanced cancer.
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00042900
- Testing
- pyroxamide
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Septic Shock
Therapeutic Plasma Exchange in Adult Patients With Severe Sepsis
The incidence of sepsis (severe infection) has increased over the last four decades. Severe sepsis and septic shock are among the leading causes of death for patients admitted to critical care units with mortality ranging from…
- Trial name
- NCT04057872
- Testing
- Therapeutic plasma exchange
- Where
- 2 sites in Canada
- Volunteers
- 17 people
- Sponsor
- Alberta Health Services, Calgary
Multiple Myeloma
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
This is a multicenter, randomized, open-label, Phase 3 study in participants with newly diagnosed multiple myeloma to evaluate the benefits of teclistamab in combination with lenalidomide and teclistamab alone versus lenalidomide…
- Trial name
- MajesTEC-4 (NCT05243797)
- Testing
- Teclistamab, Lenalidomide
- Where
- 212 sites in United States, Argentina and 23 more
- Volunteers
- 1,594 people
- Sponsor
- European Myeloma Network B.V.
Multiple Myeloma
A Study of Combination Therapy With Venetoclax, Daratumumab and Dexamethasone (With and Without Bortezomib) in Participants With Relapsed or Refractory Multiple Myeloma
This is a study of venetoclax, daratumumab, and dexamethasone with and without bortezomib combination therapy to evaluate safety, tolerability, and efficacy of these combinations in participants with relapsed or refractory…
- Trial name
- NCT03314181
- Testing
- Dexamethasone, Daratumumab, Venetoclax
- Where
- 40 sites in United States, Australia and 5 more
- Volunteers
- 156 people
- Sponsor
- AbbVie
Multiple Myeloma
Platform Study of Belantamab Mafodotin as Monotherapy and in Combination With Anti-cancer Treatments in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)
B-cell maturation antigen (BCMA) is a target present on tumor cells in participants with multiple myeloma. Belantamab mafodotin (GSK2857916); is an antibody-drug conjugate (ADC) containing humanized anti-BCMA monoclonal antibody…
- Trial name
- DREAMM 5 (NCT04126200)
- Testing
- Belantamab mafodotin, GSK3174998, Feladilimab
- Where
- 38 sites in United States, Brazil and 11 more
- Volunteers
- 208 people
- Sponsor
- GlaxoSmithKline
Multiple Myeloma
A Study of JNJ-54767414 (Daratumumab) in Combination With Lenalidomide and Dexamethasone in Japanese Participants With Previously Untreated Multiple Myeloma Who Are Ineligible for High-dose Therapy and Autologous Stem Cell Transplantation
The purpose of this study is to evaluate the safety of daratumumab when combined with lenalidomide and dexamethasone in Japanese participants with newly diagnosed multiple myeloma who are not candidates for high-dose chemotherapy…
- Trial name
- NCT02918331
- Testing
- Daratumumab (16 mg/kg), Lenalidomide, Dexamethasone
- Where
- 5 sites in Japan
- Volunteers
- 7 people
- Sponsor
- Janssen Pharmaceutical K.K.
Chronic Myeloproliferative Disorders, Leukemia
Busulfan, Fludarabine, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Stem Cell Transplant for Hematologic Cancer
RATIONALE: Giving low doses of chemotherapy, such as fludarabine and busulfan, before a donor peripheral blood stem cell transplant helps stop the growth of cancer cells.
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- Bu Flu TBI (NCT00245037)
- Testing
- therapeutic allogeneic lymphocytes, busulfan, cyclosporine
- Where
- United States
- Volunteers
- 147 people
- Sponsor
- OHSU Knight Cancer Institute
Autoimmune Diseases
PK of Meropenem in Patients on Plasma Exchange
Therapeutic plasma exchange (TPE) has been shown to be an important procedure for treatment of a variety of refractory immune complex disorders, such as Guillain-Barré syndrome and neuromyelitis optica.
- Trial name
- NCT05042271
- Testing
- meropenem
- Where
- Thailand
- Volunteers
- 15 people
- Sponsor
- Prince of Songkla University
Relapsed/Refractory Multiple Myeloma
AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)
This trial is a Phase 1b/2, open-label, multicenter study of AZD0120, a CD19/BCMA dual CAR T-cell therapy, in adult subjects with relapsed/refractory multiple myeloma.
- Trial name
- DURGA-1 (NCT05850234)
- Testing
- AZD0120
- Where
- 36 sites in United States
- Volunteers
- 232 people
- Sponsor
- AstraZeneca
Refractory Multiple Myeloma, Stage I Multiple Myeloma
Vaccine Therapy in Treating Patients With Multiple Myeloma Who Have Undergone Stem Cell Transplantation
The purpose of this trial is to test the safety and immune response to four immunizations with this vaccine made from a protein produced by the patient's tumor.
- Conditions
- Refractory Multiple Myeloma, Stage I Multiple Myeloma, Stage II Multiple Myeloma, Stage III Multiple Myeloma
- Trial name
- NCT00002787
- Testing
- autologous immunoglobulin idiotype-KLH conjugate vaccine, sargramostim, aldesleukin
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
Multiple Myeloma
An Clinical Study of NKG2D-CAR-NK Cells for the Treatment of Refractory Recurrent Multiple Myeloma
Multiple myeloma (MM) is a malignant disease characterized by the abnormal proliferation of clonal plasma cells. However, multiple myeloma remains an incurable disease and requires the exploration of more effective treatment…
- Trial name
- NCT06379451
- Testing
- NKG2D Chimeric Antigen Receptor NK Cell Injection
- Where
- China
- Volunteers
- 9 people
- Sponsor
- Changzhou No.2 People's Hospital
Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma
Lenalidomide With or Without Rituximab in Treating Patients With Progressive or Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Prolymphocytic Leukemia, or Non-Hodgkin Lymphoma Previously Treated With Donor Stem Cell Transplant
This phase II trial studies how well giving lenalidomide with or without rituximab works in treating patients with progressive or relapsed chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), prolymphocytic…
- Conditions
- Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Cutaneous B-cell Non-Hodgkin Lymphoma
- Trial name
- NCT01419795
- Testing
- lenalidomide, rituximab, pharmacological study
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Fred Hutchinson Cancer Center
Plasma Cell Myeloma
SAR650984, Pomalidomide and Dexamethasone in Combination in RRMM Patients
Primary Objectives: Part A: To evaluate the safety and determine the recommended dose of SAR650984 in combination with pomalidomide (P) and dexamethasone (d), in patients with Relapsed/Refractory Multiple Myeloma (RRMM).
- Trial name
- PomdeSAR (NCT02283775)
- Testing
- Isatuximab SAR650984, Pomalidomide, Dexamethasone
- Where
- 13 sites in United States
- Volunteers
- 54 people
- Sponsor
- Sanofi
Relapsed/Refractory Multiple Myeloma (MM)
Study of Naive HBI0101 CAR-T Therapy in Relapsed/Refractory Multiple Myeloma
A Phase 1a/1b Open-Label Study with Dose Escalation and Expansion Phases to Evaluate Safety and Preliminary Efficacy of Naïve HBI0101 CART Therapy for the Treatment of Relapsed/Refractory Multiple Myeloma.
- Trial name
- NCT07333430
- Testing
- Naive HBI0101 CAR-T
- Where
- Israel
- Volunteers
- 60 people
- Sponsor
- Hadassah Medical Organization
Chronic Hepatitis C
Safety, PK and Efficacy of 15 Days of SCY-635 Treatment in Hepatitis C Patients
This study will examine the effectiveness of 15 days of therapy with SCY-635 in reducing hepatitis C virus (HCV) RNA levels.
- Trial name
- NCT01290965
- Testing
- SCY-635
- Where
- 2 sites in United States
- Volunteers
- 57 people
- Sponsor
- Scynexis, Inc.
Advanced Lymphoma, Advanced Malignant Solid Neoplasm
Testing MLN0128 (TAK-228) as Potentially Targeted Treatment in Cancers With TSC1 or TSC2 Genetic Changes (MATCH - Subprotocol M)
This phase II MATCH treatment trial tests how well MLN0128 (TAK-228) works in treating patients with cancer that has certain genetic changes called TSC1 or TSC2 mutations.
- Conditions
- Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm
- Trial name
- NCT06390865
- Testing
- Biopsy Procedure, Biospecimen Collection, Computed Tomography
- Where
- United States
- Volunteers
- 49 people
- Sponsor
- National Cancer Institute (NCI)
Primary Hypertension
Effects of Telmisartan/Hydrochlorothiazide Treatment in Hypertensive Patients Under Real-life Setting
One of the most common adverse effects resulting from the therapy with thiazides, thiazide-like diuretics and loop diuretics is increased potassium secretion.
- Trial name
- POTASSIUM (NCT01392534)
- Testing
- Telmisartan/hydrochlorothiazide (Pritor Plus, BAY98-7103)
- Where
- Poland
- Volunteers
- 1,586 people
- Sponsor
- Bayer
Multiple Myeloma
UARK 2003-33, Total Therapy III
There have been two previous Total Therapy studies for multiple myeloma (MM) at the Myeloma Institute for Research and Therapy (MIRT): Total Therapy I (from 1989 through 1994) and Total Therapy II (from 1996 to 2004).
- Trial name
- NCT00081939
- Testing
- Velcade, Thalidomide
- Where
- United States
- Volunteers
- 303 people
- Sponsor
- University of Arkansas
Lateral Epicondylitis (Tennis Elbow)
Platelet Rich Plasma Injection vs Percutaneous Tenotomy for Common Extensor Tendinopathy
This is a randomized control trial comparing the use of leukocyte rich platelet rich plasma injections to percutaneous tenotomy for the treatment of chronic common extensor tendinopathy.
- Trial name
- NCT04384809
- Testing
- Leukocyte rich platelet rich plasma, Percutaneous Tenotomy
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- University Hospitals Cleveland Medical Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.